Payment overview · 2025
General Payments
$15,068.50
144 reported records · 21 companies
Healthcare provider profile · identity verified
Anish A Sheth, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Gastroenterology · PRINCETON, NJ · NPI 1336235191
Verified facts
What the public records show
CMS Open Payments records show Anish A Sheth, MD received $15,068.50 in general payments during 2025 across 144 reported records.
Phathom Pharmaceuticals, Inc. accounted for 51.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Rinvoq, Stelara, Voquezna, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rinvoq by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported STELARA as an associated drug or biological on 23706 records involving 7279 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Stelara by this doctor in 2024.
Phathom Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VOQUEZNA as an associated drug or biological on 90302 records involving 33442 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Voquezna by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trulance by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $7,784.48 | 51.7% | 16 | 2025 |
| Celltrion USA Inc. | Unresolved — no canonical attribution shown | $4,851.96 | 32.2% | 17 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $750.07 | 5.0% | 40 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $243.52 | 1.6% | 10 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $202.61 | 1.3% | 10 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $179.27 | 1.2% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $126.89 | 0.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $126.07 | 0.8% | 6 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $124.51 | 0.8% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $124.39 | 0.8% | 6 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $103.83 | 0.7% | 5 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $88.54 | 0.6% | 5 | 2025 |
| Lucid Diagnostics Inc. | Unresolved — no canonical attribution shown | $86.86 | 0.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $71.14 | 0.5% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $48.32 | 0.3% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $36.52 | 0.2% | 2 | 2025 |
| Pharmacosmos Therapeutics Inc. | Unresolved — no canonical attribution shown | $36.03 | 0.2% | 2 | 2025 |
| Intercept Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.32 | 0.2% | 2 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $20.85 | 0.1% | 1 | 2025 |
| Mauna Kea Technologies, Inc. | Unresolved — no canonical attribution shown | $15.83 | 0.1% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $15.49 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7,310.00 | 4 |
| Consulting Fee | $4,613.75 | 6 |
| Food and Beverage | $3,069.45 | 131 |
| Travel and Lodging | $56.00 | 1 |
| Education | $19.30 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $7,784.48 | 16 | 2025 |
Source payment records
|
|||||
| ZYMFENTRA Normalized: zymfentra |
Biological | Celltrion USA Inc. | $4,709.81 | 7 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $677.39 | 35 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $529.44 | 32 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $243.52 | 10 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $202.61 | 10 | 2025 |
Source payment records
|
|||||
| VEGZELMA Normalized: vegzelma |
Biological | Celltrion USA Inc. | $142.15 | 10 | 2025 |
Source payment records
|
|||||
| ENTYVIO Normalized: entyvio |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $129.92 | 6 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $126.89 | 2 | 2025 |
Source payment records
|
|||||
| OMVOH Normalized: omvoh |
Drug | Lilly USA, LLC | $126.07 | 6 | 2025 |
Source payment records
|
|||||
| General - Hemostasis Normalized: general hemostasis |
Device | Boston Scientific Corporation | $124.51 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $124.39 | 6 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $103.83 | 5 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $88.54 | 5 | 2025 |
Source payment records
|
|||||
| SIMPONI Normalized: simponi |
Biological | Janssen Biotech, Inc. | $87.61 | 4 | 2025 |
Source payment records
|
|||||
| SIMPONI ARIA Normalized: simponi aria |
Biological | Janssen Biotech, Inc. | $87.61 | 4 | 2025 |
Source payment records
|
|||||
| STELARA Normalized: stelara |
Biological | Janssen Biotech, Inc. | $87.61 | 4 | 2025 |
Source payment records
|
|||||
| VELSIPITY Normalized: velsipity |
Drug | PFIZER INC. | $71.14 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $54.03 | 4 | 2025 |
Source payment records
|
|||||
| EOHILIA Normalized: eohilia |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $49.35 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $48.32 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $44.38 | 3 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $36.52 | 2 | 2025 |
Source payment records
|
|||||
| MONOFERRIC Normalized: monoferric |
Drug | Pharmacosmos Therapeutics Inc. | $36.03 | 2 | 2025 |
Source payment records
|
|||||
| XELJANZ Normalized: xeljanz |
Drug | PFIZER INC. | $33.70 | 2 | 2025 |
Source payment records
|
|||||
| OCALIVA Normalized: ocaliva |
Drug | Intercept Pharmaceuticals, Inc. | $31.32 | 2 | 2025 |
Source payment records
|
|||||
| IQIRVO Normalized: iqirvo |
Drug | Ipsen Biopharmaceuticals, Inc | $20.85 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $18.65 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $15.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| RINVOQ rinvoq |
2025 | Rinvoq | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| STELARA stelara |
2025 | Stelara | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VOQUEZNA voquezna |
2025 | Voquezna | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | STELARA open payments reported associated product |
CMS Open Payments — General Payments 23706 supporting records · 7279 recipient NPIs · example record 1174257377 |
Stelara · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Phathom Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | VOQUEZNA open payments reported associated product |
CMS Open Payments — General Payments 90302 supporting records · 33442 recipient NPIs · example record 1219216983 |
Voquezna · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Famotidine | Famotidine | 185 | 65 |
| Omeprazole | Omeprazole | 100 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 60 | 23 |
| Cholestyramine | Cholestyramine (With Sugar) | 44 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | 18 |
| Clenpiq | Sod Picosulf/Mag Ox/Citric Ac | 31 | 31 |
| Xifaxan | Rifaximin | 30 | suppressed |
| Linzess | Linaclotide | 28 | suppressed |
| Lactulose | Lactulose | 27 | suppressed |
| Voquezna | Vonoprazan Fumarate | 27 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | 12 |
| Opium Tincture | Opium Tincture | 18 | suppressed |
| Trulance | Plecanatide | 16 | suppressed |
| Desipramine Hcl | Desipramine Hcl | 13 | suppressed |
| Rinvoq | Upadacitinib | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Ursodiol | Ursodiol | 13 | suppressed |
| Adalimumab-Fkjp(Cf) Pen | Adalimumab-Fkjp | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Stelara | Ustekinumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $15,068.50 · 144 records | Phathom Pharmaceuticals, Inc. | CREON, Cologuard Collection Kit, DUPIXENT, ENTYVIO, EOHILIA, General - Hemostasis, Heplisav-B, IBSRELA, IQIRVO, LINZESS, MAVYRET, MONOFERRIC, OCALIVA, OMVOH, REZDIFFRA, RINVOQ, SIMPONI, SIMPONI ARIA, SKYRIZI, STELARA, TREMFYA, UPLIZNA, VEGZELMA, VELSIPITY, VOQUEZNA, VOWST, XELJANZ, XIFAXAN, ZYMFENTRA | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error